Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why Zynerba Pharmaceuticals, Kratos Defense, Rogers Communications, and Two Other Stocks Are on Investors’ Radars Today

Stocks are in the red on Monday following Fed Chair Janet Yellen’s speech on Friday, in which she said the US economy is still facing the reverberations of 2008-2009 crisis, which can only be undone by aggressive steps.

Meanwhile, investors are paying close attention to some of the stocks today, including Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), Syneron Medical Ltd. (NASDAQ:ELOS), Omeros Corporation (NASDAQ:OMER), Rogers Communications Inc. (USA) (RCI) Rogers Communications Inc. (USA) (NYSE:RCI), and Kratos Defense & Security Solutions, Inc (NASDAQ:KTOS). This article discusses the reasons behind the movement of  these stocks, and assesses hedge fund sentiment towards them.

By analyzing the equity portfolios of some 750 investors, we can see what stocks they are collectively bullish on and use this data to compile a portfolio that can outperform the market. We have determined through this process that the best strategy is to follow the 15 most popular small-cap picks among hedge funds, which have delivered an alpha of around 81 basis points per month in our backtests covering the period between 1999 and 2012 (see more details).

stock, market, marketing, street, wall, banking, investment, trader, trading, backgrounds, graph, data, growth, business, board, forecasting, ticker, global, number, abstract,

Zynerba Pharmaceuticals Updates on ZYN001, ZYN002

Specialty pharmaceutical company Zynerba Pharmaceuticals Inc(NASDAQ:ZYNE) is in the spotlight today after the company released a press update on its fibromyalgia and peripheral neuropathic pain drug ZYN001 and permeation-enhanced gel ZYN002. Zynerba now expects to begin Phase 1 clinical trials for ZYN001 in the first half of 2017 and Phase 2 clinical trials are planned to commence in the second half of 2017, while ZYN002 is on track to report topline results in the first half of 2017. The statement said Phase 2 clinical trials are being performed in patients with refractory epilepsy and knee pain associated with osteoarthritis. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)’s CEO Armando Anido  said the company has made a “tremendous” progress in transforming ZYN001 into an optimized transdermal patch that balances efficacy with patient convenience. Mr. Anido added that the company has completed several prototypes which are smaller and more patient-friendly as compared to the original design. Just five funds out of over 750 funds tracked by Insider Monkey were bullish on Zynerba Pharmaceuticals Inc(NASDAQ:ZYNE) at the end of the second quarter.

Follow Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)
Trade (NASDAQ:ZYNE) Now!

Syneron Medical Announces Management Changes, Preliminary Revenue

Syneron Medical Ltd. (NASDAQ:ELOS)’s stock is gaining value today after the company announced a few management changes, and disclosed preliminary revenue for the third quarter. The Israel-based aesthetics medical products company said Philippe A. Schaison, who comes from Allergan Plc, is joining the company as CEO of Syneron Candela North America and Global Executive Vice President Strategy and Business Development. Co-founder of Alma Lasers, a cosmetic laser solutions company, Yariv Matzliach is joining Syneron as Executive Vice President, Distribution Channels. Paul Little, who has served in Allergan Medical Aesthetics, is joining Syneron as Global Chief Operating Officer.  The company expects third-quarter revenue to come in at $70 million to $72 million, up by approximately 14%-17% year-over-year. Analysts were expecting a revenue of $66.7 million. The statement said the revenue was spearheaded by the company’s emerging products. Total Body Shaping revenue in the third quarter 2016 was approximately $14 million, 40% year-over-year, mainly from UltraShape sales. Richard Mashaal’s Rima Senvest Management owns 3.84 million shares of Syneron Medical Ltd. (NASDAQ:ELOS) as of the end of the June quarter.

Follow Syneron Medical Ltd. (NASDAQ:ELOS)
Trade (NASDAQ:ELOS) Now!

On the next page, we will see why shares of Omeros, Rogers Communcations and Kratos Defense are trending today.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.